Melatonin
Melatonin has been studied in 923 papers since 1986: 213 trials and 58 observational studies in people, 315 in animals, 30 in cells, 286 reviews; 154 in the past year. It is an approved medicine. The newest paper, Nov 11, 2026: “Constructing functionalized cartilage organoids by preserving mitochondrial homeostasis to accelerate cartilage repair”.
923 papers study it171 more mention it1,236 findingsUpdated
Research on it is growing 9% slower than aging research as a whole: 44 papers in the latest year counted
Part of Rhonda Patrick's supplement routineMore supplements
32 new papers in 30 daysSee all 882 papers on melatonin
At a glance
Melatonin extends lifespan and reduces oxidative stress in mice in reports from independent labs, which also report improved human sleep. A mouse result shows no clear lifespan effect, and some human trials show no clear sleep benefit. Human observational data link melatonin with higher heart failure hospitalization; some papers report company ties, and companies sponsor trials across its uses.
1,236 findings in 507 papers from 1986 to 2026, 38 of them since April 2026
Independent labs found the same change in cells, worms or flies, mice and people. 265 independent labs in 45 countries; 210 trials, 3 about aging, 57 with no results posted.
“sleep quality was assessed to be better in the melatonin group than that in the placebo group with a mean (SD) of 69.7 (21.2) and 60.7 (26.3), respectively (p = 0.029).”
88 of its findings point the other way.
- 265 independent labs in 45 countries
- 88 findings against
- 210 trials, 3 about aging, 57 with no results posted
- Funders: National Natural Science Foundation of China and others
- 11 of 1,125 findings with company ties
- 10 of 210 trials sponsored by its developers
- Human trial112
- Humans51
- Animals285
- Model organisms6
- Cells26
- In silico3
Studies in people
See all 91 studies of melatonin in people91 studies gave melatonin to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases ghrelin4.35 ± 0.90 pg/mL vs. 4.78 ± 0.75 pg/mL; p = 0.013 no change: Has no effect on 2-arachidonoylglycerol no change: Has no effect on hedonic appetite intensity | Randomized trial8 weeks | 41 peopleWomen35.68 ± 7.51 yearsOverweight or obesity and high hedonic appetite | Scientific reports, Oct 18, 2026 |
down: Decreases low-density lipoprotein cholesterol down: Decreases triglyceride | Randomized trial12 weeks | 38 peopleWomenPostmenopausal women | Experimental gerontology, Oct 10, 2026 |
up: Increases bone mineral density up: Improves quality of life | Randomized trial6 months | 60 peopleWomen≥45 yearsMidlife adults; Older adults; Postmenopausal women; with calcium and vitamin D supplementation | International Journal of Drug Delivery Technology, Jun 29, 2026 |
up: Improves leg muscle strength up: Improves unipedal static balance | Randomized trial12 weeks | 36 peoplePost-intervention | International journal of food sciences and nutrition, Jun 24, 2026 |
| Randomized trialeight weeks | 200 peopleBothaged 18 to 50 yearsAdults aged 18 to 50 years who met the DSM-5 diagnostic criteria for sleep disturbance | Clocks & sleep, Mar 27, 2026 |
What did lifespan studies of melatonin find?
DrugAgeDrugAge records 12 results from 5 papers: 5 in mice, 4 in P. tetraurelia and 3 in D. melanogaster. Average lifespan is the mean or the median, as each paper reports it.
- MiceCBA, females, 20 ppm water during night for 5 consecutive days every week (month?), from 6 months+5% average+7% maximum
- P. tetraurelia10 mg/L+20.8% average+14.8% maximum
- D. melanogasterOregon R, 100 µg/ml+14% average+33% maximum
- MiceC57BL/6, males, 10 ppm water during night, from 19 months+17% average
- P. tetraurelia10 mg/L+10.8% average+5.1% maximum
- D. melanogasterCanton S, females, 0.08% per unit mass culture medium+5.5% average
What did studies of melatonin find?
448Studies of melatonin measured 448 outcomes; the most studied are oxidative stress and ROS signaling (30 studies), cellular senescence (27) and inflammation (23).
Oxidative stress and ROS signaling
downin rats10downin reviews7downin humans5downin mice4+4
30 studies
Oxidative stress and ROS signaling
downin rats10downin reviews7downin humans5downin mice4+4
Melatonin decreases oxidative stress and ROS signaling in humans (diabetic hemodialysis patients) (β = -0.21 μmol/L, 95% CI -0.36 to -0.06).
“plasma malondialdehyde (β = -0.21 μmol/L, 95% CI -0.36 to -0.06, P = .005)”
Human trialdiabetic hemodialysis patients2 x 5mg/day12 weeksn = 60
Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation
Melatonin decreases oxidative stress and ROS signaling in humans under methadone maintenance treatment (β -0.31, 95% CI -0.57 to -0.05).
“malondialdehyde (β -0.31; 95% CI, -0.57, -0.05; P = 0.02) and protein carbonyl (β -0.06; 95% CI, -0.09, -0.04; P < 0.001)”
Human trialunder methadone maintenance treatmentcapsules10 mg12 weeksn = 54
Addiction biology
Melatonin decreases oxidative stress and ROS signaling.
“Melatonin complements these actions through mitochondrial redox protection, preservation of bioenergetics, and circadian regulation.”
Review
Preprints.orgPreprint
Melatonin decreases oxidative stress and ROS signaling in rats (LPS-induced).
“attenuating LPS-induced oxidative stress and inflammatory damage in placental tissue and trophoblast cells.”
AnimalsLPS-inducedplacentafemales
European journal of pharmacology
Melatonin decreases oxidative stress and ROS signaling in mice.
“The administration of the antioxidant melatonin to 16-month-old mice significantly ameliorated oxidative stress”
Animalsgastrointestinal tract
Early melatonin partially delays gut aging in mice
Biochimica et biophysica acta. Molecular basis of disease
Melatonin decreases oxidative stress and ROS signaling in experimental studies of age-related vascular diseases.
“Experimental studies consistently indicate that melatonin can reduce oxidative stress, inflammatory signaling, apoptosis, mitochondrial dysfunction, vascular smooth muscle cell phenotypic switching, and endothelial impairment.”
Reviewin experimental studies of age-related vascular diseases
Molecular biology reports
Melatonin protects against oxidative stress and ROS signaling in humans.
“Furthermore, melatonin promotes amyloid clearance via the glymphatic and lymphatic systems, protects neurons from oxidative damage, and reduces Tau hyperphosphorylation.”
Review
International journal of molecular sciences
Melatonin decreases oxidative stress and ROS signaling in aged IR-injured rats.
“MLT treatment significantly alleviated liver injury, reducing oxidative stress and inflammatory markers expression.”
Animalsin aged IR-injured ratsliver1 mg/100 g body weightmales
Journal of physiology and biochemistry
Melatonin decreases oxidative stress and ROS signaling in malnourished young male rats.
“Both MLT administration and TE reduced these adverse effects, improving behavioral performance, slowing CSD, and attenuating prooxidant markers.”
Animalsin malnourished young male ratssubcutaneouscortex10 mg/kg on alternate daysP25 to P55males
Frontiers in aging neuroscience
Melatonin decreases oxidative stress and ROS signaling in humans (WMD: -1.54 μmol/L, 95% CI: -2.07, -1.01).
“malondialdehyde (WMD: -1.54 μmol/L, 95% CI: -2.07, -1.01)”
Review
Nutrients
All 30Fewer
Cellular senescence
downin mice9downin reviews6downin human cells5downin cells3+3
27 studies
Cellular senescence
downin mice9downin reviews6downin human cells5downin cells3+3
Melatonin decreases cellular senescence in STZ-induced diabetic mice and high-glucose-stimulated HK-2 cells.
“melatonin effectively reduced the levels of cellular senescence marker proteins (p53, p21, p16INK4A, and γ-H2AX), decreased the SA-β-gal positive staining area”
Animalsin STZ-induced diabetic mice and high-glucose-stimulated HK-2 cellskidney
European journal of pharmacology
Melatonin decreases cellular senescence in plaques and in hydrogen peroxide-stimulated VSMCs; suppression abolished by luzindole.
“Melatonin markedly suppressed VSMC senescence in both plaques and hydrogen peroxide-stimulated VSMCs”
Animalsin plaques and in hydrogen peroxide-stimulated VSMCs; suppression abolished by luzindolevascular smooth muscle cells
Redox biology
Melatonin decreases cellular senescence.
“melatonin can alleviate DPSCs senescence by inhibiting the expression of matrix metalloproteinase”
Reviewdental pulp stem cell
Senescence of dental pulp stem cells: phenotypes, underlying mechanisms and regulatory molecules
Human cell
Melatonin decreases cellular senescence in bone marrow mesenchymal stem cell senescence.
“We assess current interventions aimed at reducing BMSC senescence, with an emphasis on pharmacological methods like melatonin and antioxidants, alongside nonpharmacological strategies, such as exercise and dietary supplementation with omega-3 fatty acids.”
Reviewin bone marrow mesenchymal stem cell senescence
Current molecular medicine
Melatonin decreases cellular senescence in cells.
“melatonin inhibited macrophage senescence and improved chemotherapy responsiveness”
Cellsmacrophages
The Journal of biological chemistry
Melatonin decreases cellular senescence in acute skeletal muscle injury model.
“Melatonin treatment was found to attenuate the injury-induced senescence of FAPs.”
Animalsin acute skeletal muscle injury model100 μM in vitro, 20 mg/kg/day in vivo5 days in vitro, 15 days in vivo
Stem cell research & therapy
Melatonin decreases cellular senescence in senescent pituitary cells.
“melatonin reduced the levels of senescence-related markers in senescent pituitary cells”
Cellsin senescent pituitary cellspituitary
International journal of biological macromolecules
Melatonin decreases cellular senescence.
“Melatonin has been shown to reduce senescence and promote autophagy within disc cells, vital for clearing out damaged cellular components”
Reviewintervertebral disc
Pain physician
Melatonin decreases cellular senescence in mice after optic nerve crush.
“Melatonin also suppressed ONC-induced senescence and apoptosis index.”
Animalsafter optic nerve crushretina
Biochimica et biophysica acta. Molecular basis of disease
Melatonin decreases cellular senescence in high glucose conditions.
“In vitro, melatonin inhibited STAT3 phosphorylation and lowered cellular senescence and apoptosis markers, in a manner similar to the STAT3 inhibitor S3I-201.”
Cellsin high glucose conditions
Life sciences
All 28Fewer
Inflammation
downin rats7downin reviews7downin mice5downin humans4
23 studies
Inflammation
downin rats7downin reviews7downin mice5downin humans4
Melatonin decreases inflammation in humans under methadone maintenance treatment (β -0.15, 95% CI -0.27 to -0.02).
“melatonin intake resulted in a significant reduction in serum high sensitivity C-reactive protein (β -0.15; 95% CI, -0.27, -0.02; P = 0.02)”
Human trialunder methadone maintenance treatmentcapsules10 mg12 weeksn = 54
Addiction biology
Melatonin decreases inflammation in experimental studies of age-related vascular diseases.
“Experimental studies consistently indicate that melatonin can reduce oxidative stress, inflammatory signaling, apoptosis, mitochondrial dysfunction, vascular smooth muscle cell phenotypic switching, and endothelial impairment.”
Reviewin experimental studies of age-related vascular diseases
Molecular biology reports
Melatonin decreases inflammation in humans (WMD: -0.59 mg/L, 95% CI: -0.94, -0.23).
“C-reactive protein (WMD: -0.59 mg/L, 95% CI: -0.94, -0.23)”
Review
Nutrients
Melatonin decreases inflammation in rats.
“melatonin attenuated the expression of pro-inflammatory markers”
Animalsintraperitoneally10 mg/kg30 daysmales
Neurochemical research
Melatonin inhibits inflammation (Alzheimer's disease pathology).
“regulating amyloid beta (Aβ)-induced neuroinflammation”
ReviewAlzheimer's disease pathology
Melatonin Supplementation in Alzheimer's disease: The Potential Role in Neurogenesis
Molecular neurobiology
Melatonin decreases inflammation.
“melatonin's promising antioxidant, anti-inflammatory, and immunomodulatory properties”
Review
Melatonin supplementation: new insights into health and disease
Sleep & breathing = Schlaf & Atmung
Melatonin decreases inflammation in mice (aged mice on high-fat diet).
“It also suppressed inflammatory markers (e.g., TNF-α, NLRP3, NF-κB, IL-1β, and CEBPB)”
Animalsaged mice on high-fat dietepididymal white adipose tissue
Antioxidants (Basel, Switzerland)
Melatonin decreases inflammation in intermittent hypoxia-exposed mice.
“melatonin treatment reduced the levels of the proinflammatory cytokines, interleukin-1β, interleukin-6, and tumor necrosis factor-α”
Animalsin intermittent hypoxia-exposed mice
Psychoneuroendocrinology
Melatonin decreases inflammation (Alzheimer's disease).
“melatonin exerts a significant role in AD prevention and treatment via its antioxidant effects, reducing neuroinflammation, and Aβ.”
ReviewAlzheimer's disease
Hormones (Athens, Greece)
Melatonin decreases inflammation in patients with diabetes (SMD = -0.75, 95% CI: -1.37, -0.12).
“melatonin can lead to significant reductions in levels of C-reactive protein (CRP) [SMD = -0.75; 95% CI: -1.37, -0.12; P = 0.018]”
Reviewin patients with diabetesn = 823
Clinical nutrition ESPEN
All 23Fewer
Apoptosis
downin mice7downin rats3downin human cells1downin humans1+3
14 studies
Apoptosis
downin mice7downin rats3downin human cells1downin humans1+3
Melatonin decreases apoptosis in experimental studies of age-related vascular diseases.
“Experimental studies consistently indicate that melatonin can reduce oxidative stress, inflammatory signaling, apoptosis, mitochondrial dysfunction, vascular smooth muscle cell phenotypic switching, and endothelial impairment.”
Reviewin experimental studies of age-related vascular diseases
Molecular biology reports
Melatonin decreases apoptosis in humans.
“Anti-oxidants such as coenzyme Q10, melatonin, and nicotinamide have been shown to mitigate oxidative stress, enhance mitochondrial function, reduce apoptosis, and im-prove the quality of oocytes”
Review
Frontiers in endocrinology
Melatonin decreases apoptosis in granulosa cells.
“promote autophagy and reduce apoptosis of GCs”
Cellsin granulosa cellsgranulosa cell
Exogenous melatonin alleviates premature ovarian failure by regulating granulosa cell autophagy
NPJ Regenerative medicine
Melatonin decreases apoptosis in mice after optic nerve crush.
“Melatonin also suppressed ONC-induced senescence and apoptosis index.”
Animalsafter optic nerve crushretina
Biochimica et biophysica acta. Molecular basis of disease
Melatonin induces apoptosis in mouse cells.
“Melatonin promoted apoptosis of RAW264.7 cells”
CellsRAW264.7
Bone & joint research
Melatonin decreases apoptosis in high glucose conditions.
“In vitro, melatonin inhibited STAT3 phosphorylation and lowered cellular senescence and apoptosis markers, in a manner similar to the STAT3 inhibitor S3I-201.”
Cellsin high glucose conditions
Life sciences
Melatonin decreases apoptosis in kidneys of DN mice.
“Melatonin treatment decreased the positive area of senescence-associated galactosidase (SA-β-gal) staining and the number of TUNEL-positive cells in kidneys of DN mice.”
Animalsin kidneys of DN micekidney
Life sciences
Melatonin decreases apoptosis in mice (cardiac aging).
“melatonin recovered mitochondrial architecture, reduced apoptosis and multivesicular bodies' formation”
Animalscardiac agingcardiomyocyte
Antioxidants (Basel, Switzerland)
Melatonin decreases apoptosis in mice (aged heart).
“Melatonin supplementation also had an anti-apoptotic action”
Animalsaged heartheart
Melatonin/Nrf2/NLRP3 Connection in Mouse Heart Mitochondria during Aging
Antioxidants (Basel, Switzerland)
Melatonin decreases apoptosis in rats (propofol-treated).
“decreased the apoptotic cell counts in the regions of HIP and PFC.”
Animalspropofol-treatedhippocampus and prefrontal cortex
Prophylactic Melatonin Treatment Ameliorated Propofol-Induced Cognitive Dysfunction in Aged Rats
Neurotoxicity research
All 15Fewer
Sleep quality
upin humans7no changein humans3
10 studies
Sleep quality
upin humans7no changein humans3
Melatonin improves sleep quality in humans.
“Results of the analysis of percentage difference between pre‐ and post‐intervention for the above‐mentioned factors, plus menopausal status, after adjusting for age, showed an isolated effect of group (p < 0.001) and shift (p = 0.023), but not menopausal status (p = 0.86), on sleep quality on days off (Table of Supporting Information”
Human trial3 monthsfemalesn = 46
Journal of pineal research
Melatonin improves sleep quality in humans (on days off) (+35.33% (p < 0.001)).
“Sleep quality improved by 35.33% on days off in the intervention group (p < 0.001)”
Human trialon days off0.3 mgfemalesn = 46
Journal of pineal research
Melatonin improves sleep quality in humans (hospitalized patients; before-and-after comparison).
“Results showed significant improvement after melatonin across all measures, with increased sleep duration, faster sleep onset, fewer awakenings, and better reported sleep quality.”
Human trialhospitalized patients; before-and-after comparison
Cureus
Melatonin showed no clear effect on sleep quality in humans (advanced primary open-angle glaucoma).
“No significant differences were found between melatonin and placebo for any sleep or quality of life outcomes.”
Human trialadvanced primary open-angle glaucomaoral5 mg30 daysn = 64
Ophthalmology. Glaucoma
Melatonin improves sleep quality in humans (p < 0.001).
“Melatonin administration, however, caused a significant improvement in sleep quality which was significantly impaired in NS versus NNS at baseline (p < 0.001).”
Human trialsustained-release2 mg12 weeksn = 24
Pharmacological research
Melatonin showed no clear effect on sleep quality in humans (postoperative orthopedic trauma patients) (PSQI 5.6 vs 6.1, P = 0.615).
“melatonin PSQI = 5.6, placebo PSQI = 6.1, P = 0.615”
Human trialpostoperative orthopedic trauma patients5 mg4 weeks
Injury
Melatonin improves sleep quality in humans (critically ill ICU patients) (69.7 vs 60.7, p = 0.029).
“sleep quality was assessed to be better in the melatonin group than that in the placebo group with a mean (SD) of 69.7 (21.2) and 60.7 (26.3), respectively (p = 0.029).”
Human trialcritically ill ICU patientsoral10 mgup to seven consecutive nightsn = 203
Critical care medicine
Melatonin improves sleep quality in humans (chronic kidney disease) (WMD = -3.75, 95% CI: -6.92, -0.57).
“improved sleep quality (PSQI: WMD = -3.75, 95% CI: -6.92, -0.57, p = 0.021”
Reviewchronic kidney disease
Frontiers in nutrition
Melatonin improves sleep quality in humans.
“improving sleep quality and addressing specific neurodegenerative diseases”
Review
Melatonin supplementation: new insights into health and disease
Sleep & breathing = Schlaf & Atmung
Melatonin improves sleep quality in COVID-19 patients.
“improving the quality of sleep, which could also help COVID-19 patients achieve better clinical outcomes.”
Reviewin COVID-19 patients
Sleep, Dietary Melatonin Supplementation, and COVID-19
Current medicinal chemistry
All 11Fewer
SIRT1
upin rats6upin mice1upin rat cells1upin reviews1
9 studies
SIRT1
upin rats6upin mice1upin rat cells1upin reviews1
Melatonin increases SIRT1 in mice after optic nerve crush.
“melatonin partially rescued the expression of SIRT1 in RGC 3 days after ONC”
Animalsafter optic nerve crushretinal ganglion cells3 days after optic nerve crush
Biochimica et biophysica acta. Molecular basis of disease
Melatonin increases SIRT1 in diabetic elderly female rat model.
“the highest retinal SIRT1 expression values were obtained in the diabetes + melatonin (G4) group.”
Animalsin diabetic elderly female rat modelretinal tissue4 weeksfemalesn = 24
Melatonin protects retinal tissue damage in streptozotocin-induced aged rats
Archives of gerontology and geriatrics
Melatonin increases SIRT1 in streptozotocin-induced diabetic aged female rats.
“suppressed antioxidant activity and decreased GLUT4, SIRT1, and PGC-1α gene expression in heart tissue can be reversed by the combination of resveratrol, melatonin, and resveratrol + melatonin”
Animalsin streptozotocin-induced diabetic aged female ratsresveratrol, melatonin, and resveratrol + melatoninheart5 mg/kg/day4 weeksfemalesn = 48
Experimental gerontology
Melatonin activates SIRT1 in rat cells (ovariectomy-derived BMMSCs).
“Melatonin reversed the differentiation switch of OVX-BMMSCs from osteogenesis to adipogenesis by activating the SIRT1 signaling pathway.”
Cellsovariectomy-derived BMMSCs
Journal of orthopaedic translation
Melatonin increases SIRT1 in rats (non-exercised ovariectomized rats).
“Melatonin treatment or its co-administration with HRT upregulated the expressions of IL-10 and SIRT1”
Animalsnon-exercised ovariectomized ratsheart and thoracic aorta4 mg/kg/dayfemales
Inflammation
Melatonin increases SIRT1 in ovariectomized non-exercised rats.
“Melatonin treatment or its co-administration with HRT upregulated the expressions of IL-10 and SIRT1”
Animalsin ovariectomized non-exercised ratsoralheart and thoracic aorta4 mg/kg/day10 weeksfemales
Research SquarePreprint
Melatonin increases SIRT1 in ALAN-exposed rats.
“while upregulating the aging (Sirt 1) gene expression in both young and old melatonin supplemented ALAN exposed groups.”
Animalsin ALAN-exposed ratsoralbrain10 mg Kg−110 daysmales
Biogerontology
Melatonin increases SIRT1.
“Furthermore, melatonin upregulates SIRT-1, which reduces NF-κB activity by de-acetylation of NF-κB subunits.”
Review
Control of Mesenchymal Stromal Cell Senescence by Tryptophan Metabolites
International journal of molecular sciences
Melatonin increases SIRT1 in rats (melatonin from 24 h before MCA occlusion (PrevT)).
“while hippocampal levels of sirtuin 1 (SIRT1) and B-cell lymphoma 2 (Bcl-2) increased”
Animalsmelatonin from 24 h before MCA occlusion (PrevT)hippocampus24 h before surgery to 7 days after
International journal of molecular sciences
Cognitive function
upin mice2upin rats2no changein humans1downin humans1+2
7 studies
Cognitive function
upin mice2upin rats2no changein humans1downin humans1+2
Melatonin showed no clear effect on cognitive function in humans (Mild Cognitive Impairment).
“Accordingly, there were no significant differences between melatonin and placebo interventions in any of the secondary outcomes.”
Human trialMild Cognitive Impairmentoral25 mg12 weeksn = 40
Journal of pineal research
Melatonin improves cognitive function in intermittent hypoxia-exposed mice.
“melatonin attenuated IH-induced impairment of learning and memory in aged mice”
Animalsin intermittent hypoxia-exposed mice
Psychoneuroendocrinology
Melatonin improves cognitive function in doxorubicin-treated rats.
“Mel and Met equally improved those brain pathologies, resulting in cognitive improvement in DOX-treated rats.”
Animalsin doxorubicin-treated rats10 mg/kg/day30 consecutive daysmalesn = 8
Neurotoxicology
Melatonin showed no clear effect on cognitive function in ovariectomized rats.
“Heart rates and memory performances of the postmenopausal rats were not changed significantly by none of the applications.”
Animalsin ovariectomized rats10 weeksfemales
Research SquarePreprint
Melatonin impairs cognitive function in humans (healthy-subjects).
“In healthy-subjects, although daytime melatonin treatment notably decreased in accuracy by correct responses [SMD: -0.74 (-1.03; -0.45) p < 0.00001]”
Reviewhealthy-subjectsdaytime
Neuroscience and biobehavioral reviews
Melatonin improves cognitive function in humans (mild stage of AD).
“melatonin significantly improved MMSE score in mild stage of AD [MD: 1.89 (0.96; 2.82) p < 0.0001].”
Reviewmild stage of AD
Neuroscience and biobehavioral reviews
Melatonin improves cognitive function in aged rats fed a high-fat diet.
“MLT reversed HFD-induced cognitive decline as measured by a water maze test”
Animalsin aged rats fed a high-fat diet
Journal of pineal research
Melatonin improves cognitive function in 3xTg-AD mice.
“melatonin reversed cognitive impairment and dementia-associated behaviors of anxiety and apathy”
Animalsin 3xTg-AD mice10 mg/kg daily6 to 12 months of age
Melatonin induces mechanisms of brain resilience against neurodegeneration
Journal of pineal research
Quality of life
upin humans5no changein humans1
6 studies
Quality of life
upin humans5no changein humans1
Melatonin improves quality of life in humans with calcium and vitamin D supplementation.
“the physical domain showed significant improvement in the melatonin group (p=0.042)”
Human trialwith calcium and vitamin D supplementation3 mg daily6 monthsfemales
Effect of Melatonin on bone health and quality of life In Postmenopausal women
International Journal of Drug Delivery Technology
Melatonin improves quality of life in humans (breast cancer patients receiving antihormone medications).
“The quality of life and sexual function were enhanced by a four-week melatonin treatment.”
Human trialbreast cancer patients receiving antihormone medications3 mg twice a dayfour weeksn = 60
Advanced biomedical research
Melatonin improves quality of life in humans during pulmonary rehabilitation in patients with COPD (-6.9 ± 3.0 vs. -1.9 ± 2.4, p < 0.01).
“and quality of life (-6.9 ± 3.0 vs. -1.9 ± 2.4; p < 0.01), compared to the placebo group.”
Human trialduring pulmonary rehabilitation in patients with COPD3 mg/day12 weeksn = 39
Respiratory medicine
Melatonin improves quality of life in hemodialysis patients.
“EX-MEL induced better results in some domains of QoL compared with EX-PLA.”
Human trialin hemodialysis patients12 weeksn = 33
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
Melatonin showed no clear effect on quality of life in humans (postoperative orthopedic trauma patients).
“Melatonin treatment did not significantly improve subjective sleep quality, pain, quality of life or opioid use.”
Human trialpostoperative orthopedic trauma patients5 mg4 weeks
Injury
Melatonin improves quality of life in humans (P = 0.002).
“scores of HDRS, HARS, and total QLI in the melatonintreated group (P ≤0.001, 0.001, and 0.002, respectively).”
Human trialtablets3 mg3 monthsn = 60
Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia
Malondialdehyde
downin humans2downin mice2downin rats2
6 studies
Malondialdehyde
downin humans2downin mice2downin rats2
Melatonin decreases malondialdehyde in humans (adjusted for baseline measures) (P<0.001).
“After treatment, considerable differences were only seen between the two groups in serum MDA (P<0.001) and LDL-C (P=0.007) concentrations, adjusted for baseline measures.”
Human trialadjusted for baseline measures6 mg/day12 weeks
Clinical rheumatology
Melatonin decreases malondialdehyde in humans (chronic kidney disease) (-1.28 μmol/L, 95% CI: -2.50, -0.06).
“reduced malondialdehyde (MDA: -1.28 μmol/L, 95% CI: -2.50, -0.06, p = 0.039”
Reviewchronic kidney disease
Frontiers in nutrition
Melatonin decreases malondialdehyde in cuprizone-treated young and aging mice.
“Introducing melatonin to mice of any age reduced the number of GFAP+-, CD3+- cells and their subpopulations, macrophage activation, and MDA content.”
Animalsin cuprizone-treated young and aging miceintraperitoneal injectionbrain1 mg/kg
Frontiers in cellular neuroscience
Melatonin decreases malondialdehyde in diabetic elderly female rat model.
“Again in our study, the highest retinal MDA values were obtained in the diabetes group (G3).”
Animalsin diabetic elderly female rat modelretinal tissue4 weeksfemalesn = 24
Melatonin protects retinal tissue damage in streptozotocin-induced aged rats
Archives of gerontology and geriatrics
Melatonin decreases malondialdehyde in rats (ovariectomized rats; administration at 9 am compared with 9 pm).
“lower values of Type I collagen cross-linked C-telopeptide, procollagen type 1 N propeptide, and malondialdehyde (p = 0.013)”
Animalsovariectomized rats; administration at 9 am compared with 9 pm30 mg/kg/day12 weeksn = 10
Bone & joint research
Melatonin decreases malondialdehyde in mice.
“The increases in TAOC and SOD level and decreases in MDA were detected in ovaries and uterus from melatonin-treated mice compared to the controls.”
Animalsovary and uteruslong-termfemales
Journal of pineal research
TNF-alpha
downin humans2downin rats2no changein humans1downin M. unguiculatus1
6 studies
TNF-alpha
downin humans2downin rats2no changein humans1downin M. unguiculatus1
Melatonin decreases TNF-alpha in women with polycystic ovary syndrome (P < 0.05).
“Serum levels of tumor necrosis factor-α (TNF-α) declined significantly in the melatonin and co-supplementation groups compared to baseline (P < 0.05).”
Human trialin women with polycystic ovary syndrome8 weeksfemalesn = 84
Biological trace element research
Melatonin decreases TNF-alpha in ageing Mongolian gerbils.
“reduced the levels of circulating tumor necrosis factor-α (TNF-α), immune globulin G (IgG) and corticosterone (CORT).”
Animalsin ageing Mongolian gerbils
Comparative biochemistry and physiology. Toxicology & pharmacology : CBP
Melatonin decreases TNF-alpha in humans (WMD = - 2.24 pg/ml; 95% CI - 3.45, - 1.03; P < 0.001).
“Melatonin supplementation significantly decreased TNF-α and IL-6 levels [(WMD = - 2.24 pg/ml; 95% CI - 3.45, - 1.03; P < 0.001”
Review
European journal of nutrition
Melatonin decreases TNF-alpha in HFD-fed rats.
“hippocampal levels of TNF-α in HFD-fed rats were reduced by MLT treatment”
Animalsin HFD-fed ratshippocampus
Journal of pineal research
Melatonin decreases TNF-alpha in rats (melatonin from 24 h before MCA occlusion (PrevT)).
“experienced a significant decrease in the levels of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β)”
Animalsmelatonin from 24 h before MCA occlusion (PrevT)cortex and hippocampus24 h before surgery to 7 days after
International journal of molecular sciences
Melatonin showed no clear effect on TNF-alpha in humans (patients with metabolic syndrome and related disorders) (SMD = -1.87, 95% CI -3.81, 0.07).
“however, it did not affect tumor necrosis factor-α (TNF-α) concentrations (SMD = - 1.87; 95% CI - 3.81, 0.07; P = 0.05; I2: 94.4).”
Reviewpatients with metabolic syndrome and related disorders
Inflammopharmacology
Body weight
downin humans2no changein humans1downin rats1upin rats1
5 studies
Body weight
downin humans2no changein humans1downin rats1upin rats1
Melatonin decreases body weight in humans.
“According to our findings, weight and BMI reduced significantly at 12th week in the both groups.”
Human trial12 weeksn = 44
BioMed research international
Melatonin decreases body weight in humans (along with a weight-loss diet) (p = 0.01).
“for the last six weeks, significant reductions of these parameters were observed only in the melatonin group (p = 0.01).”
Human trialalong with a weight-loss diet3-milligram per day12 weeks
BioMed research international
Melatonin showed no clear effect on body weight in humans.
“However, no substantial effects were observed on BW, BMI, WC, and SBP compared to the control group.”
Reviewn = 1,543
Heliyon
Melatonin decreases body weight in rats (ovariectomized).
“supplemented with low, medium, and high doses of Mel for 8 weeks exhibited reduced BW gain, perirenal fat mass, and gonads fat mass”
Animalsovariectomized8 weeksfemales
Nutrients
Melatonin decreases body weight in humans (SMD -0.48, 95% CI -0.94 to -0.02, P < 0.01).
“melatonin supplementation significantly reduced body weight (standardized mean difference, -0.48; 95% confidence interval, -0.94 to -0.02; P = <0.01; I2 = 92%).”
Review
Nutrition (Burbank, Los Angeles County, Calif.)
Melatonin increases body weight in rats with BDL-induced biliary cirrhosis.
“There was an increase in weight gain and phase angle in the groups treated with MLT with/or EX comparing to the BDL group.”
Animalsin rats with BDL-induced biliary cirrhosismales
Experimental and molecular pathology
HOMA-IR
downin humans3no changein humans1downin reviews1
5 studies
HOMA-IR
downin humans3no changein humans1downin reviews1
Melatonin showed no clear effect on HOMA-IR in humans.
“There were no intergroup differences in CAVI, mtDNA, HOMA-IR, or SBP from the baseline to week six between the placebo and melatonin groups.”
Human trialsix weeksfemalesn = 38
International journal of environmental research and public health
Melatonin decreases HOMA-IR in patients with Parkinson's disease (β -0.47, 95% CI -0.80 to -0.13).
“Additionally, consuming melatonin significantly decreased serum insulin levels (β -1.79 μIU/mL; 95% CI, -3.12, -0.46; P = 0.009), homeostasis model of assessment-insulin resistance (HOMA-IR)”
Human trialin patients with Parkinson's disease10 mg/day12 weeksn = 60
Clinical neurology and neurosurgery
Melatonin decreases HOMA-IR in humans (polycystic ovary syndrome) (β -0.28; 95% CI, -0.50, -0.05).
“melatonin administration, compared with the placebo, significantly reduced serum insulin (β -1.20 μIU/mL; 95% CI, -2.14, -0.26; P = 0.01), homeostasis model of assessment-insulin resistance (HOMA-IR)”
Human trialpolycystic ovary syndromecapsules10 mg12 weeksfemalesn = 58
Journal of affective disorders
Melatonin decreases HOMA-IR (28 out of 33 studies).
“melatonin supplementation reduced fasting plasma glucose (FPG, 14 out of 29 studies), fasting insulin (22 out of 28 studies), HOMA-IR (28 out of 33 studies), and increased QUICKI”
Review10 mg
Diabetes & metabolic syndrome
Melatonin decreases HOMA-IR in humans.
“melatonin administration significantly reduced insulin levels and homeostasis model assessment of insulin resistance (HOMA-IR)”
Review
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
Mortality
downin A. cerana1no changein humans1upin humans1downin humans1HR 2.09
4 studies
Mortality
downin A. cerana1no changein humans1upin humans1downin humans1HR 2.09
Melatonin showed no clear effect on mortality in humans (medically hospitalised older patients) (3.64% vs 1.85%, p=1.000).
“28-day mortality (3.64% vs 1.85%, p=1.000)”
Human trialmedically hospitalised older patients5 mg or 8 mgup to 5 daysn = 109
BMJ open
Melatonin is linked with higher mortality in humans (HR 2.09 (95% CI 1.99–2.18)).
“All-cause mortality was higher in melatonin users (5, 118 [7.8%] vs 2, 820 [4.3%]; HR 2.09, 95% CI 1.99–2.18).”
Humans5 years
AHA Scientific Sessions 2025 abstract
Melatonin decreases mortality in A. cerana (at 37 °C).
“most pronounced effect at 37 °C, where mortality was significantly reduced.”
Model organismsat 37 °C20 μg/mL
Insects
Melatonin decreases mortality in patients admitted to intensive care units.
“melatonin decreases the risks of severe complications, such as thrombosis and sepsis, and mortality rates.”
Reviewin patients admitted to intensive care units
Sleep, Dietary Melatonin Supplementation, and COVID-19
Current medicinal chemistry
Fasting blood glucose
downin humans4
4 studies
Fasting blood glucose
downin humans4
Melatonin decreases fasting blood glucose in patients with diabetic nephropathy (β = -10.64 mg/dL; 95% CI: -20.37 to -0.90; P < .05).
“Melatonin administration significantly reduced plasma fasting glucose (β = -10.64 mg/dL; 95% CI: -20.37 to -0.90; P < .05)”
Human trialin patients with diabetic nephropathyplasma10 mg/d12 weeksn = 60
Iranian journal of kidney diseases
Melatonin decreases fasting blood glucose in humans (supplementation in adults) (WMD = -2.66 mg/dl, 95%CI: -4.53 to -0.80).
“melatonin supplementation significantly reduced fasting blood sugar (WMD = -2.66 mg/dl, 95%CI: -4.53 to -0.80, n = 27)”
Reviewsupplementation in adults
Nutrition & metabolism
Melatonin decreases fasting blood glucose in humans (WMD: -11.63 mg/dL, 95% CI: -19.16, -4.10).
“fasting blood glucose (WMD: -11.63 mg/dL, 95% CI: -19.16, -4.10)”
Review
Nutrients
Melatonin decreases fasting blood glucose in diabetes (mean difference: -4.65; 95% CI: -8.06, -1.23; p = < 0.01).
“Our meta-analysis showed significant results for fasting blood glucose [mean difference: -4.65; 95% CI: -8.06, -1.23; p = < 0.01; I2 = 58%]”
Reviewin diabetes
Clinical nutrition (Edinburgh, Scotland)
C-reactive protein
downin humans3no changein humans1
4 studies
C-reactive protein
downin humans3no changein humans1
Melatonin showed no clear effect on C-reactive protein in humans (diabetic nephropathy) (P = 0.81).
“We did not observe any significant change in C-reactive protein (CRP) concentrations after melatonin intake (P = 0.81).”
Human trialdiabetic nephropathy10 mg/day24 weeksn = 32
Clinical nutrition ESPEN
Melatonin decreases C-reactive protein in patients with Parkinson's disease (β -0.94 mg/L, 95% CI -1.55 to -0.32).
“melatonin supplementation resulted in a significant reduction in serum high sensitivity C-reactive protein (hs-CRP) (β -0.94 mg/L; 95% CI, -1.55, -0.32; P = 0.003)”
Human trialin patients with Parkinson's disease10 mg/day12 weeksn = 60
Clinical neurology and neurosurgery
Melatonin decreases C-reactive protein in humans (diabetic hemodialysis patients) (β = -1.92 mg/L, 95% CI -3.02 to -0.83).
“melatonin administration resulted in a significant reduction in serum high sensitivity C-reactive protein (β = -1.92 mg/L, 95% CI -3.02 to -0.83, P = .001)”
Human trialdiabetic hemodialysis patients2 x 5mg/day12 weeksn = 60
Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation
Melatonin decreases C-reactive protein in humans (patients with metabolic syndrome and related disorders) (SMD = -1.80, 95% CI -3.27, -0.32).
“melatonin supplementation significantly reduced C-reactive protein (CRP) (SMD = - 1.80; 95% CI - 3.27, - 0.32; P = 0.01; I2: 95.2)”
Reviewpatients with metabolic syndrome and related disorders
Inflammopharmacology
All 448Fewer
What is melatonin linked with?
48Studies link melatonin with 48 measures, among them postoperative delirium, circadian clock and clinical pregnancy rate.
Postoperative delirium
downin humans2RR 0.72
2 studies
Postoperative delirium
downin humans2RR 0.72
Melatonin lowers the risk of postoperative delirium in humans (elderly surgical patients) (RR 0.72; 95% CI 0.56-0.92; p = 0.009).
“Overall, postoperative delirium occurred in 188/895 patients (21.0%) receiving melatonergic agents and 254/893 patients (28.4%) in control groups, corresponding to a significant reduction in POD (RR 0.72; 95% CI 0.56-0.92; p = 0.009).”
Reviewelderly surgical patients
Journal of clinical anesthesia
Melatonin lowers the risk of postoperative delirium in humans (elderly postoperative patients).
“subgroup analysis showed that melatonin significantly reduced the occurrence of POD”
Reviewelderly postoperative patients
Aging clinical and experimental research
Circadian clock
upin humans1mixedin reviews1
2 studies
Circadian clock
upin humans1mixedin reviews1
Melatonin is associated with circadian clock.
“promising chronobiotics such as melatonin, resveratrol, and their analogs are analysed in terms of their alignment with geroprotector criteria”
Review
Chronobiotics as potential geroprotectors
Advances in gerontology = Uspekhi gerontologii
Melatonin is associated with circadian clock in humans.
“In reviewing the literature, a clear circadian melatonin profile with a nocturnal peak at 3 am and lower daytime levels was observed in the healthy, elderly population.”
Review
Melatonin profile in healthy, elderly subjects - A systematic literature review
Chronobiology international
Clinical pregnancy rate
upin humans1
1 study
Clinical pregnancy rate
upin humans1
Melatonin is associated with clinical pregnancy rate (patients aged ≥ 38 years) (46.0% vs. 20.3%).
“For patients ≥ 38 years, melatonin significantly improved clinical pregnancy rates (46.0% vs. 20.3%, P < 0.01), ongoing pregnancy rates (36.5% vs. 15.3%, P < 0.01), and live birth rates (33.3% vs. 15.3%, P < 0.05).”
Humanspatients aged ≥ 38 yearsat least eight weeks
Reproductive biology and endocrinology : RB&E
Melatonin is associated with clinical pregnancy rate in humans (Undergoing IVF-frozen embryo transfer cycles; compared with control) (46.0% vs. 20.3%).
“increasing clinical pregnancy rates (46.0% vs. 20.3%, P < 0.01)”
HumansUndergoing IVF-frozen embryo transfer cycles; compared with control2 mg daily≥ 8 weeksfemales
Reproductive biology and endocrinology : RB&E
Ongoing pregnancy rate
upin humans1
1 study
Ongoing pregnancy rate
upin humans1
Melatonin is associated with ongoing pregnancy rate (patients aged ≥ 38 years) (36.5% vs. 15.3%).
“For patients ≥ 38 years, melatonin significantly improved clinical pregnancy rates (46.0% vs. 20.3%, P < 0.01), ongoing pregnancy rates (36.5% vs. 15.3%, P < 0.01), and live birth rates (33.3% vs. 15.3%, P < 0.05).”
Humanspatients aged ≥ 38 yearsat least eight weeks
Reproductive biology and endocrinology : RB&E
Melatonin is associated with ongoing pregnancy rate in humans (Undergoing IVF-frozen embryo transfer cycles; compared with control) (36.5% vs. 15.3%).
“ongoing pregnancy rates (36.5% vs. 15.3%, P < 0.01)”
HumansUndergoing IVF-frozen embryo transfer cycles; compared with control2 mg daily≥ 8 weeksfemales
Reproductive biology and endocrinology : RB&E
Live birth rate
upin humans1
1 study
Live birth rate
upin humans1
Melatonin is associated with live birth rate (patients aged ≥ 38 years) (33.3% vs. 15.3%).
“For patients ≥ 38 years, melatonin significantly improved clinical pregnancy rates (46.0% vs. 20.3%, P < 0.01), ongoing pregnancy rates (36.5% vs. 15.3%, P < 0.01), and live birth rates (33.3% vs. 15.3%, P < 0.05).”
Humanspatients aged ≥ 38 yearsat least eight weeks
Reproductive biology and endocrinology : RB&E
Melatonin is associated with live birth rate in humans (Undergoing IVF-frozen embryo transfer cycles; compared with control) (33.3% vs. 15.3%).
“live birth rates (33.3% vs. 15.3%, P < 0.05)”
HumansUndergoing IVF-frozen embryo transfer cycles; compared with control2 mg daily≥ 8 weeksfemales
Reproductive biology and endocrinology : RB&E
Arrhythmia
upin humans1
1 study
Arrhythmia
upin humans1
Melatonin is linked with a higher risk of arrhythmia in humans (0.80% vs. 0.71%, sRR 1.14 [1.06-1.22]).
“melatonin users had a significantly higher 5-year risk of arrythmia compared with controls (0.80% vs. 0.71%, sRR 1.14 [1.06-1.22])”
Humans5-year
Melatonin may be linked to slightly higher irregular heartbeat risk
ESC Congress 2026 abstract
Obesity incidence
downin humans1HR 0.51
1 study
Obesity incidence
downin humans1HR 0.51
Melatonin is associated with obesity incidence in humans (Q3 versus Q1 in the fully adjusted multivariable Cox model) (49% lower risk; HR 0.51, 95% CI 0.34-0.75).
“participants in Q3 (20,894.5-26,276.5 ng/day) had a 49% lower risk of incident obesity (HR 0.51; 95% CI 0.34-0.75; p = 0.001).”
HumansQ3 versus Q1 in the fully adjusted multivariable Cox modelDietary melatonin20,894.5-26,276.5 ng/day (Q3)Mean 4.4 yearsBoth; 65.8% womensn = 3,736
Nutrition, metabolism, and cardiovascular diseases : NMCD
Hypertension
downin humans1OR 0.45
1 study
Hypertension
downin humans1OR 0.45
Melatonin is linked with a lower risk of hypertension in humans (one-sample Mendelian randomization) (OR = 0.45, P = 0.015).
“suggested a protective effect of higher serum melatonin levels on hypertension risk (OR = 0.45, P = 0.015)”
Humansone-sample Mendelian randomization
Human genetics
Parkinson's disease
upin humans1HR 1.63
1 study
Parkinson's disease
upin humans1HR 1.63
Melatonin is associated with Parkinson's disease in humans (compared with benzodiazepines in patients with sleep disorders) (HR 1.63, 95% CI 1.51-1.76).
“Parkinson's disease (HR 1.63, 95% CI 1.51-1.76; HR 1.44, 95% CI 1.33-1.57)”
Humanscompared with benzodiazepines in patients with sleep disorders
Scientific reports
Dementia
upin humans1HR 2.09
1 study
Dementia
upin humans1HR 2.09
Melatonin is associated with dementia in humans (compared with benzodiazepines in patients with sleep disorders) (HR 2.09, 95% CI 2.01-2.16).
“Melatonin use was associated with higher observed risk of all-cause dementia compared with benzodiazepines (HR 2.09, 95% CI 2.01-2.16)”
Humanscompared with benzodiazepines in patients with sleep disorders
Scientific reports
Change in sit-to-stand repetitions
upin humans1
1 study
Change in sit-to-stand repetitions
upin humans1
Melatonin is associated with change in sit-to-stand repetitions in humans (OL/Melatonin group) (r = 0.958, p = 0.04).
“and positively associated with melatonin levels in the OL/Melatonin group (r = 0.958, p = 0.04).”
Human trialOL/Melatonin group12 monthsfemales
Journal of pineal research
Poor sleep
downin humans1RR 0.21
1 study
Poor sleep
downin humans1RR 0.21
Melatonin lowers the risk of poor sleep in humans (critically ill ICU patients) (RR 0.21, 95% CI 0.06-0.71).
“whereas 3.1% and 14.6% had very poor sleep (risk ratio, 0.21; 95% CI, 0.06-0.71), respectively.”
Human trialcritically ill ICU patientsoral10 mgup to seven consecutive nightsn = 203
Critical care medicine
All 48Fewer
What acts on melatonin?
19Studies name 19 things that act on melatonin, among them resistance training, high-intensity interval training and Korean dance program.
Resistance training
upin humans2
2 studies
Resistance training
upin humans2
Resistance training increases melatonin in humans.
“the elastic band group exhibited a significant increase in melatonin levels”
Human trialeight weeksfemales
Korean Journal of Sports Science
Resistance training increases melatonin in humans (elderly T2DM patients with sleep disturbances).
“Melatonin increased only in the intervention group (P<0.05)”
Human trialelderly T2DM patients with sleep disturbances12 weeksn = 180
Pakistan journal of pharmaceutical sciences
High-intensity interval training
upin humans1
1 study
High-intensity interval training
upin humans1
High-intensity interval training increases melatonin in humans.
“serum levels of the melatonin hormone (11.2 ± 2.3, p < 0.001), TAC (48.7 ± 7.1, p < 0.002), COX (3.7 ± 0.75, p < 0.001), and a higher percentage of lymphocyte apoptosis (5.2 ± 0.31, p < 0.003) were significantly increased following HIIT interventions”
Human trial12 weeksmalesn = 80
Medicina (Kaunas, Lithuania)
High-intensity interval training increases melatonin in humans (11.2 ± 2.3, p < 0.001).
“Data analysis showed a significant increase in the expression levels of the melatonin hormone (11.2 ± 2.3, p < 0.001)”
Human trial12 weeksmalesn = 80
Medicina (Kaunas, Lithuania)
Korean dance program
upin humans1
1 study
Korean dance program
upin humans1
Korean dance program increases melatonin in humans (pooled across six studies, older women) (effect size = .770, 95% CI .088–1.452 (moderate effect)).
“moderate effects were observed for growth hormone (effect size = .577, 95% CI = .195~.960) and melatonin (effect size = .770, 95% CI = .088~1.452).”
Human trialpooled across six studies, older womenfemales
Journal of Sport and Dance Science
Photobiomodulation
no changein humans1
1 study
Photobiomodulation
no changein humans1
Photobiomodulation showed no clear effect on melatonin in humans (insomnia symptoms).
“No significant changes were observed in actigraphy-derived sleep indicators or melatonin measures.”
Human trialinsomnia symptomstwo weeksn = 59
Photodiagnosis and photodynamic therapy
Institutionalization
upin humans1
1 study
Institutionalization
upin humans1
Institutionalization is linked with higher melatonin in humans (institutionalized individuals vs individuals living with family members).
“Blood cortisol (p = 0.0309) and melatonin (p = 0.0407) were also elevated.”
Humansinstitutionalized individuals vs individuals living with family members
Hormonal and Cytokine Imbalances Promote a Proinflammatory Profile in Institutionalized Elderly
Brain sciences
Yoga
upin humans1
1 study
Yoga
upin humans1
Yoga increases melatonin in humans (pooled SMD 0.37 (95% CI 0.09 to 0.66)).
“the role of yogic techniques on melatonin levels, with a pooled SMD of 0.37 (95% - CI: [0.09; 0.66])”
Review
Meta-analysis of the Effect of Yogic Techniques on Melatonin Levels: Implications for Sleep Health
International journal of yoga
Light at night
downin cynomolgus monkeys1
1 study
Light at night
downin cynomolgus monkeys1
Light at night decreases melatonin in cynomolgus monkeys.
“intensity-dependently reduced melatonin secretion”
Animals10 monthsn = 137
Nocturnal Light Pollution Synergistically Impairs Glucose Metabolism With Age and Weight in Monkeys
Journal of diabetes research
Physical exercise
upin reviews1
1 study
Physical exercise
upin reviews1
Physical exercise increases melatonin.
“can also lead to an increase in melatonin levels.”
Review
Hormones (Athens, Greece)
SARS-COV-2 infection
upin humans1
1 study
SARS-COV-2 infection
upin humans1
SARS-COV-2 infection is linked with higher melatonin in elderly patients.
“There was an increase in IL-6, IL-17, and melatonin in the group of elderly individuals with infection.”
Humansin elderly patients
International journal of molecular sciences
Constant light
no changein rhesus monkeys1
1 study
Constant light
no changein rhesus monkeys1
Constant light showed no clear effect on melatonin in rhesus monkeys.
“There were no significant changes in melatonin secretion both in young and old animals.”
Animals24 h light/day, 330-400 lux4 to 8 weeksfemales
Frontiers in endocrinology
Electromagnetic field shielding bed
upin humans1
1 study
Electromagnetic field shielding bed
upin humans1
Electromagnetic field shielding bed increases melatonin in humans.
“Hormones, serotonin (Fig. A, p < 0.001), oxytocin (Fig. B, p < 0.001) and melatonin (Fig. C, p < 0.05), increased significantly after sleeping for two months on HOGO bed.”
Human trialtwo monthsn = 28
Environmental health : a global access science source
Blue-enriched polychromatic light
downin humans1
1 study
Blue-enriched polychromatic light
downin humans1
Blue-enriched polychromatic light decreases melatonin in humans (young adults; compared with non-blue-enriched light).
“In young individuals, light exposure at 6500 K significantly attenuated the increase in endogenous melatonin levels”
Human trialyoung adults; compared with non-blue-enriched light6500 K~40 lx2 hn = 31
Age-related neuroendocrine and alerting responses to light
GeroScience
All 19Fewer
Has melatonin been tested in people?
3 of 210 about agingYes: 213 trials and 58 observational studies in people have been published, and 209 trials are registered.
About aging
Approved
Jun 29, 2007Sleep Initiation and Maintenance Disorders, primary insomnia
Sep 20, 2018Sleep Initiation and Maintenance Disorders, insomnia
Nov 7, 2022Sleep Initiation and Maintenance Disorders, primary insomnia
Repurposing
Phase 3Status unknown3 trials
Phase 3Completed2 trials
Phase 3Status unknown4 trials
Phase 3Terminated1 trial
Phase 3Completed4 trials
Phase 3Terminated3 trials
40 of 126Fewer
Every condition in trials
Attention deficit disorder with hyperactivity
Phase 4Status unknown4 trials
Dental anxiety
Phase 4Completed1 trial
Health Condition 1: O- Medical and Surgical
Phase 3Status unknown3 trials
Dyssomnias
Phase 3Completed2 trials
IVF
Phase 3Status unknown1 trial
Squamous cell carcinoma of head and neck
Phase 3Results posted1 trial
All 16Fewer
Readouts due
- Feb 20, 2027
Adjunctive Melatonin Gel With MINST on GCF Galectin-3 and IL-1 in Stage III-IV Periodontitis
Phase 2Not yet recruiting
- Mar 2027
- Sep 30, 2027
Active, not recruiting
- Oct 30, 2027
Melatonin in Posterior Mandible Extraction Socket
Phase 2Not yet recruiting
Stopped
NCT01033565TerminatedSleep-wake disorder
Unsuccessful in recruiting appropriate subjects.
NCT02654314TerminatedDelirium
Lack of resources to complete the study. Descriptive statistics for the outcome measures collected are provided.
NCT02454855TerminatedTumor
The study stopped for futility after the DSMB.
NCT01598259TerminatedBurns
lack or enrollment, funding depletion
NCT02190838TerminatedMelanoma
Preliminary terminated due to inefficacy
NCT03540485TerminatedMultiple sclerosis
Early termination due to operational feasibility reasons, resulting from a slow recruitment rate and logistical and financial difficulties that prevent reaching the planned sample size within the study schedule.
All 8Fewer
Who is developing melatonin?
1 company: Neurim Pharmaceuticals.
- Companies
- Neurim PharmaceuticalsPhase 2primary insomnia
Trial sponsors
Company1 trialPhase 4100 people
Company5 trialsPhase 31,092 people
Company2 trialsPhase 3295 people
Ache Laboratorios Farmaceuticos
Company1 trialPhase 2/3307 people
Company1 trialPhase 218 people
Company1 trialPhase 1/284 people
Company1 trialPhase 197 people
Company1 trialPhase 140 people
Funding
14 grants since 2016Japan Society for the Promotion of Science¥55.6MGouvernement du Canada | Canadian Institutes of Health ResearchCA$44.5KNational Institute of Diabetes and Digestive and Kidney Diseases$117K
National Institute of Diabetes and Digestive and Kidney DiseasesJohns Hopkins University$117K2026–2028
Japan Society for the Promotion of ScienceTokyo Metropolitan Institute of Gerontology¥6.2M2025–2029
Japan Society for the Promotion of ScienceTohoku University¥18.7M2025–2029
Effects of exogenous melatonin on sleep spindles in older adults with scd and mci
Gouvernement du Canada | Canadian Institutes of Health ResearchUniversity of OttawaCA$27K2024–2025
The impact of melatonin on the process of sleep dependant memory consolidation
Gouvernement du Canada | Canadian Institutes of Health ResearchUniversity of OttawaCA$17.5K2023–2024
Japan Society for the Promotion of ScienceWakayama Professional University of Rehabilitation¥3.8M2021–2024
Japan Society for the Promotion of ScienceTokyo Metropolitan Institute of Gerontology¥4.3M2021–2025
São Paulo Research Foundation2021–2026
Japan Society for the Promotion of ScienceTokyo Medical and Dental University¥4.4M2019–2023
Analysis of the relationship of melatonin and oral frailty
Japan Society for the Promotion of ScienceTokai University¥4.2M2018–2023
How this record changed
Summary rewritten as its findings changed.
As it read before
Independent labs report that melatonin extends mouse lifespan and improves human sleep quality, but some sleep studies and a mouse lifespan study show no clear benefit. Human observational work links melatonin with higher heart failure hospitalization risk. Across uses, some trials ended over a year ago without posted results; companies sponsor some trials, and some papers declare company ties.
Summary rewritten as its findings changed.
As it read before
Melatonin extends mouse lifespan and improves human sleep quality in reports from independent labs, alongside reports of no clear effect on either outcome. Three registered trials concern aging; across all uses, 56 trials ended over a year ago without posted results or citing papers. Company ties are declared in five papers, and Neurim Pharmaceuticals sponsors seven trials.
Summary rewritten as its findings changed.
As it read before
Melatonin extends mouse lifespan and reduces oxidative stress across independent labs, but other mouse results show no lifespan effect. Independent labs report improved human sleep quality, alongside trials reporting no benefit. Among assessed trial registrations, none are aging-related; 57 have no posted results or citing papers over a year after ending, and papers disclose company ties.
Summary rewritten as its findings changed.
As it read before
Independent labs report that melatonin extends mouse lifespan and improves human sleep; other reports find no effect on these outcomes, and a human study associates melatonin with heart failure hospitalization. None of the assessed trials are judged aging-related; 64 ended over a year ago without posted results or citing papers. An author is affiliated with Neurim Pharmaceuticals, which sponsors seven trials.
Summary rewritten as its findings changed.
As it read before
Melatonin extends mouse lifespan across independent labs, although other mouse studies report no effect or shorter lifespan. One group reports a human association with higher heart failure risk; the National Natural Science Foundation of China is a named funder. No trials concern aging; across uses, 64 ended over a year ago without posted results or citing papers, and seven have Neurim Pharmaceuticals sponsorship.